These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 8937420

  • 1. Kinetics of human thrombin inhibition by two novel peptide inhibitors (Hirunorm IV and Hirunorm V).
    Cappiello M, Vilardo PG, Lippi A, Criscuoli M, Del Corso A, Mura U.
    Biochem Pharmacol; 1996 Oct 25; 52(8):1141-6. PubMed ID: 8937420
    [Abstract] [Full Text] [Related]

  • 2. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
    Cirillo R, Lippi A, Subissi A, Agnelli G, Criscuoli M.
    Thromb Haemost; 1996 Sep 25; 76(3):384-92. PubMed ID: 8883275
    [Abstract] [Full Text] [Related]

  • 3. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.
    De Simone G, Lombardi A, Galdiero S, Nastri F, Della Morte R, Staiano N, Pedone C, Bolognesi M, Pavone V.
    Protein Sci; 1998 Feb 25; 7(2):243-53. PubMed ID: 9521099
    [Abstract] [Full Text] [Related]

  • 4. Thrombin-specific inhibition by and slow cleavage of hirulog-1.
    Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW.
    Biochem J; 1992 May 01; 283 ( Pt 3)(Pt 3):737-43. PubMed ID: 1290488
    [Abstract] [Full Text] [Related]

  • 5. Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors.
    Lombardi A, Nastri F, Della Morte R, Rossi A, De Rosa A, Staiano N, Pedone C, Pavone V.
    J Med Chem; 1996 May 10; 39(10):2008-17. PubMed ID: 8642559
    [Abstract] [Full Text] [Related]

  • 6. Human umbilical vein smooth muscle cells as a model to study thrombin generation and function: effect of thrombin inhibitors.
    Catalioto RM, Cucchi P, Renzetti AR, Criscuoli M, Subissi A.
    Thromb Haemost; 1996 Oct 10; 76(4):603-9. PubMed ID: 8903003
    [Abstract] [Full Text] [Related]

  • 7. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.
    Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW.
    Biochemistry; 1990 Jul 31; 29(30):7095-101. PubMed ID: 2223763
    [Abstract] [Full Text] [Related]

  • 8. Kinetic mechanism for the interaction of Hirulog with thrombin.
    Parry MA, Maraganore JM, Stone SR.
    Biochemistry; 1994 Dec 13; 33(49):14807-14. PubMed ID: 7993908
    [Abstract] [Full Text] [Related]

  • 9. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage.
    Kline T, Hammond C, Bourdon P, Maraganore JM.
    Biochem Biophys Res Commun; 1991 Jun 28; 177(3):1049-55. PubMed ID: 2059196
    [Abstract] [Full Text] [Related]

  • 10. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
    Callas DD, Hoppensteadt D, Fareed J.
    Semin Thromb Hemost; 1995 Jun 28; 21(2):177-83. PubMed ID: 7660140
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of the inhibition of alpha-thrombin by hirudin-derived fragments hirudin(1-47) and hirudin(45-65).
    Schmitz T, Rothe M, Dodt J.
    Eur J Biochem; 1991 Jan 01; 195(1):251-6. PubMed ID: 1991472
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide.
    Römisch J, Stöhr HA, Stauss H, Koschinsky R, Stüber W, Pâques EP.
    Thromb Haemost; 1994 Mar 01; 71(3):320-4. PubMed ID: 8029796
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of thrombin by synthetic hirudin peptides.
    Binnie CG, Erickson BW, Hermans J.
    FEBS Lett; 1990 Sep 17; 270(1-2):85-9. PubMed ID: 2226793
    [Abstract] [Full Text] [Related]

  • 14. Structure-function and refolding studies of the thrombin-specific inhibitor hirudin.
    Johnson PH, Sze P, Winant RC, Hudson D, Underhill P, Lazar JB, Olsen C, Almquist R.
    Haemostasis; 1991 Sep 17; 21 Suppl 1():41-8. PubMed ID: 1894196
    [Abstract] [Full Text] [Related]

  • 15. Hirulog-1 and -B2 thrombin specificity.
    Witting JI, Bourdon P, Maraganore JM, Fenton JW.
    Biochem J; 1992 Oct 15; 287 ( Pt 2)(Pt 2):663-4. PubMed ID: 1445227
    [No Abstract] [Full Text] [Related]

  • 16. Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates.
    Hortin GL, Trimpe BL.
    J Biol Chem; 1991 Apr 15; 266(11):6866-71. PubMed ID: 1849894
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
    Prasa D, Svendsen L, Stürzebecher J.
    Thromb Haemost; 1997 Oct 15; 78(4):1215-20. PubMed ID: 9364987
    [Abstract] [Full Text] [Related]

  • 18. Rational design of hirulog-type inhibitors of thrombin.
    Egner U, Hoyer GA, Schleuning WD.
    J Comput Aided Mol Des; 1994 Oct 15; 8(5):479-90. PubMed ID: 7876896
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CX-397, a novel recombinant hirudin analog having a hybrid sequence of hirudin variants-1 and -3.
    Komatsu Y, Misawa S, Sukesada A, Ohba Y, Hayashi H.
    Biochem Biophys Res Commun; 1993 Oct 29; 196(2):773-9. PubMed ID: 8240353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.